Literature DB >> 3792423

Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study.

P H Held, C G Regårdh.   

Abstract

A combined i.v. and oral dosage regimen of metoprolol early in acute myocardial infarction has been evaluated. Metoprolol 15 mg i.v. in three divided doses followed by 200 mg orally in divided doses was administered to 20 patients. The median delay from onset of pain to start of treatment was 7.5 h. Following the i.v. dose absorption of the first oral dose was prolonged in several patients, but the plasma metoprolol concentration rapidly stabilized at a mean of about 200 nmol/l. A significant correlation was found between the change in resting heart rate and the plasma concentration of metoprolol 15 min after the start of treatment. Blood pressure was not correlated with metoprolol concentration. Nine patients were restudied after 16-19 days of chronic therapy. The time to maximal plasma concentration of metoprolol on chronic treatment was reduced compared to that observed after the first oral dose. The median minimum plasma concentration during steady state averaged around 200 nmol/l and was comparable to the mean trough levels 24 and 48 h after the start of therapy. In the majority of patients, the dosage regimen rapidly produced and maintained plasma levels of metoprolol which should induce a significant degree of beta-blockade.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3792423     DOI: 10.1007/bf00981121

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors:  C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Effects of cedilanid-D in combination with metoprolol on exercise tolerance and systolic time intervals in angina pectoris.

Authors:  L G Ekelund; G Johnsson; A Melcher; L Oro
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

4.  Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.

Authors:  C G Regårdh; G Johnsson; L Jordö; P Lungborg; B A Persson; O Rönn
Journal:  J Cardiovasc Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.105

5.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

6.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1985-03       Impact factor: 29.983

7.  Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial.

Authors:  A Hjalmarson; D Elmfeldt; J Herlitz; S Holmberg; I Málek; G Nyberg; L Rydén; K Swedberg; A Vedin; F Waagstein; A Waldenström; J Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

8.  Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.

Authors:  R H Briant; R E Dorrington; D G Ferry; J W Paxton
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs.

Authors:  R Gugler; R Krist; H Raczinski; K Höffgen; G Bodem
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  10 in total
  3 in total

1.  Clinical Pharmacokinetics of Metoprolol: A Systematic Review.

Authors:  Ammara Zamir; Iltaf Hussain; Anees Ur Rehman; Waseem Ashraf; Imran Imran; Hamid Saeed; Abdul Majeed; Faleh Alqahtani; Muhammad Fawad Rasool
Journal:  Clin Pharmacokinet       Date:  2022-06-28       Impact factor: 5.577

2.  The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.

Authors:  W McClennen; B Hornestam; U E Jonsson; P Held
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

3.  The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls.

Authors:  Julia M Hebestreit; Arne May
Journal:  J Headache Pain       Date:  2017-12-19       Impact factor: 7.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.